T he main source of preventable disability after aneurysmal subarachnoid hemorrhage (SAH) is delayed cerebral ischemia (DCI), manifest by reductions in cerebral blood flow (CBF) and hence cerebral oxygen delivery (1) . Treatments for DCI focus on restoring oxygen delivery by increasing CBF to hypoperfused brain regions. Hemodynamic interventions are routinely employed for this purpose, including volume expansion, induced hypertension, and augmenAn alternative but controversial approach to improving oxygen delivery in SAH is the use of RBC transfusion to raise hemoglobin and thus arterial oxygen content (Cao 2 ) (7). Prospective controlled trials in selected populations found no advantage to liberal compared with restrictive transfusion thresholds (8) (9) (10) (11) , and current recommendations for use of stored blood in critically ill patients limit transfusion until hemoglobin concentration falls below 7 g/dL (12) (13) (14) . A small prospective randomized trial of higher goal hemoglobin after SAH found higher hemoglobin targets to be safe and feasible (15) . The risks and benefits of transfusion in SAH are not well defined.
SAH, however, may represent an important exception to those general recommendations. Transfusion trials have generally excluded (or only included few) patients with acute brain injuries at risk for cerebral ischemia. As with cardiac ischemia (16, 17) , the benefits of improving oxygen delivery to a critically hypoperfused organ may outweigh other risks in SAH patients. Recent guidelines have suggested higher hemoglobin targets for patients with acute coronary syndrome, severe sepsis, brain trauma, and SAH (18) , despite limited data to support this practice.
The question of transfusion thresholds is of particular concern in SAH patients as anemia frequently develops after SAH. Hemoglobin falls below 10 g/dL within 4 days of admission in half of SAH patients and almost all develop some degree of anemia during the period of highest risk for DCI (19) . The associated reduction in Cao 2 additionally impairs oxygen delivery in the face of reduced CBF; studies have associated anemia after SAH with poor outcomes, including more cerebral infarction (20, 21) .
However, the ability of transfusion to actually improve cerebral oxygen delivery in SAH has not been established. For decades, a policy of hemodilution was employed in an attempt to improve CBF by lowering blood viscosity; this approach has fallen out of favor with the recognition that any minimal improvement in CBF at lower hematocrit is outweighed by the fall in Cao 2 (22) . We previously reported that transfusion improved oxygen delivery and reduced the number of vulnerable regions in a small group of SAH patients with hemoglobin levels of 7-10 g/dL (23) . In this expanded cohort, we evaluated the effects of transfusion on cerebral oxygen transport in a larger number of patients across the full spectrum of anemia severity (hemoglobin levels from 7 to 13 g/dL). Our primary endpoint was the ability of transfusion to improve oxygen delivery in vulnerable brain regions. In addition, we sought to 1) determine whether, as has been proposed (24) , there is a hemoglobin threshold above which transfusion no longer improves oxygen delivery and 2) provide physiologic evidence to guide the design and interpretation of phase III studies to determine if improving oxygen delivery with transfusion leads to less DCI and infarction and better clinical outcomes.
MATERIALS AND METHODS

Patient Selection
Patients were eligible for this study if they 1) experienced spontaneous SAH; 2) had a ruptured cerebral aneurysm secured by endovascular or surgical means; 3) were at risk for DCI based on clinical grade, admission CT grade (25) , or angiographic vasospasm. Anemia was not an inclusion criterion for the study. Due to the concern that transfusion would increase viscosity and potentially reduce CBF, and thus, oxygen delivery (DO 2 ) despite a higher hemoglobin, we first enrolled patients with hemoglobin levels less than 10 g/dL. After establishing that transfusion did not impair DO 2 in those patients, we moved on to study those with hemoglobin less than 12 g/dL, and finally, those greater than 12 g/dL. Exclusion criteria included active congestive heart failure, pregnancy, or inability to obtain matched blood. Informed consent was obtained from patients or their legally authorized surrogates. The Human Research Protection Office and Radioactive Drug Research Committee of Washington University approved the study protocol. Eight of the patients included were the subject of a preliminary report (23) .
ICU Care and Data Collection
All patients with SAH were cared for in the Neurology/Neurosurgery ICU (NNICU), received nimodipine and a short course of anticonvulsants. Ruptured aneurysms were repaired by surgical or endovascular means within 24 hours of admission. Patients were maintained euvolemic by adjusting IV fluids to preserve even fluid balance. New or worsening neurologic deficits were promptly evaluated, and if no alternative cause was identified, patients underwent hemodynamic augmentation with fluids and induced hypertension, and cerebral angiography. Endovascular interventions for vasospasm included angioplasty and/or intra-arterial vasodilators. Those remaining asymptomatic underwent screening angiography around day 7. Anemia was not routinely treated with transfusion until hemoglobin fell to less than 7 g/dL.
Data collected included demographics, medical and social history, and neurologic status at admission (26) . Admission CT was rated using the modified Fisher scale (25) , and intraventricular hemorrhage was measured using the Hijdra score (27) . Cerebral angiograms were reviewed by an interventional neuroradiologist for the presence of arterial vasospasm, and graded as mild, moderate, or severe in each vascular territory.
Experimental Protocol for PET Studies
All patients were studied on the Siemens/CTI ECAT EXACT HR+ PET Scanner located in the NNICU. Image acquisition to measure CBF, cerebral blood volume (CBV), oxygen extraction fraction (OEF), and cerebral metabolic rate of oxygen consumption (CMRo 2 ) were performed as detailed previously (28) . Scans were acquired in 2D mode. Transmission scans were used for subsequent attenuation correction. All scans were calibrated for conversion of PET counts to quantitative radiotracer concentrations (29, 30) . CBF was measured by bolus injection of 15 O-labeled water by using an adaptation of the Kety autoradiographic method (31) . CBV was measured by using a brief inhalation of 15 O-labeled carbon monoxide (9) . CMRo 2 and OEF were derived from the CBF and CBV measurements and an inhalation of 15 O-labeled oxygen (32) . Cao 2 was measured using oximetry in the hospital central laboratory. A limitation of this technique is its modest resolution which requires the assumption that OEF is uniform throughout the capillary bed, an assumption that is likely not valid.
After baseline scans, the patient remained in the scanner and a single unit of RBCs (approximately 350 mL) was transfused over 1 hour and then scans were immediately repeated. An attending neurointensivist was present throughout the study, and all ongoing therapies for DCI were continued. At the time of each image acquisition, physiologic data were recorded.
PET Processing
PET scans for each patient were coregistered and aligned using Automated Image Registration software (Roger Woods, University of California, Los Angeles, CA) (31) and then coregistered to a reference brain image and resliced so data could be localized in Talairach atlas space along with the patient's CT scan in closest temporal proximity to the PET study. Using the CT images and brain atlas coordinates, an image mask was created that included the brain below the superior sagittal sinus down to the level of the pineal gland to measure global values for each variable. Spherical regions of 10-mm diameter were placed in 36 predetermined locations covering the major vascular territories as previously outlined (33) . Regions corresponding to hematoma, infarcted tissue, or ventricular system were excluded. Regional values were then calculated within each of the remaining spheres.
Data Analysis
Brain regions were considered hypoperfused and vulnerable if cerebral oxygen delivery (the product of CBF and Cao 2 ) was below 4.5 mL/100 g/min (equivalent to CBF threshold of 25 mL/100 g/min with a Cao 2 of 18 mL/dL). Data are presented as means ± sd (if normally distributed), otherwise medians with interquartile range (IQR). Global response was assessed using paired t tests or Wilcoxon signed rank test. The relationship between change in oxygen delivery and baseline Hgb (and covariates) was assessed using Pearson correlation coefficient.
We evaluated regional response using a linear mixed model to account for correlation among repeated measures in different brain regions from the same subject. We used low oxygen delivery as a factor and baseline hemoglobin as a covariate, evaluating the significance of the interaction of these terms with transfusion and calculating estimated marginal means for oxygen delivery and OEF pre-and posttransfusion in each group. Modeling was performed using PROC MIXED and contrast and estimate statements were used. All analyses were conducted using a two-sided test at a significance level of 0.05 using SAS 9.4 (SAS Institute, Cary, NC) by an experienced biostatistician.
RESULTS
Fifty-six patients were enrolled; four were not studied due to patient instability or lack of PET scanner availability. Of 52 studies performed, five were excluded for technical reasons. CBF and oxygen delivery data were available in all patients. Due to logistical limitations of our PET system, measurements of OEF and CMRo 2 were only able to be completed in 34 (72%). Characteristics of the study cohort are in Table 1 . PET was performed a median of 9 days after SAH. Women were overrepresented, both due to preponderance of women among those with SAH and requirement for anemia. Over half had angiographic vasospasm and over one third were actively being treated for DCI. Baseline Hgb was median 9.7 g/dL (IQR, 8.5-10.7) (Fig. 1) . Transfusion Table 2) .
Global Response to Transfusion
Mean baseline CBF was 43 ± 11 mL/100 g/min, corresponding to oxygen delivery of 5.5 ± 1.6 mL/100 g/min (median, 50; IQR, 34-47). Baseline CBF was not correlated with age, hemoglobin, or Glasgow Coma Scale at admission or at time of study, but was inversely correlated with baseline OEF (r = -0.63; p < 0.001). Global CBF did not differ in patients with and without DCI (41 ± 14 vs 44 ± 9; p = 0.4), although all but one of those with DCI were being actively treated with vasopressors during the PET study and had higher MAPs (126 vs 105; p < 0.001). Despite a small reduction in CBF (Table 3) , oxygen delivery increased 10%, from a median of 5.0 to 5.5 mL/100 g/min (p = 0.001). The magnitude of this response was comparable across the range of Hgb values (r = -0.17; p = 0.25) (Fig. 2) . The only variables correlated with change in oxygen delivery were baseline CBF and oxygen delivery (r = -0.44 and -0.48, both p = 0.002), indicating that patients with lower baseline perfusion responded better to transfusion. Oxygen delivery improved after transfusion in all patients with Hgb less than 8 g/dL, 84% of those with Hgb less than 9 g/dL, and 61% of those with Hgb greater than or equal to 9 g/dL (p = 0.08). There was no change in global OEF or CMRo 2 .
Responses in Vulnerable Brain Regions
After excluding regions with infarction or hematoma, 1,580 brain regions (33.5 per subject) remained for regional analysis. Four hundred forty-three (28%) were classified as vulnerable based on low baseline oxygen delivery (< 4.5 mL/100 g/min) and 303 of 1,174 (26%) had high OEF (≥ 0.5). More vulnerable regions were seen at lower Hgb (r = -0.46; p = 0.03), with a median of 13 per patient (IQR, 9-20) with low oxygen delivery if Hgb less than 9 g/dL versus 2 (0-11) at Hgb greater than 9 g/ dL (p = 0.014). Similarly, number of high OEF regions were greater in those with Hgb less than 9 g/dL (12.5, 2-21) than those with higher Hgb (6, 0-11; p = 0.06)
The rise in oxygen delivery was greater in vulnerable regions than those with normal baseline oxygen delivery (p = 0.002 for interaction of transfusion and region type in mixed model). Oxygen delivery improved by 16%, from 3.7 ± 0.5 to 4.3 ± 0.9 mL/100 g/min, in vulnerable regions compared with only a small change observed in normal regions (6.9 ± 2.1 to 7.1 ± 2.2) ( Table 3 ). This was independent of baseline Hgb (p = 0.002 after adjusting for Hgb). There was a similar rise in regional brain oxygen delivery for those with Hgb less than 10 and Hgb greater than 10 (estimate mean increase of 0.33-0.34 in both groups, p = 0.83). OEF was also reduced significantly in hypoperfused regions (0.49 ± 0.15 to 0.44 ± 0.15) compared with no change in normal regions (0.39-0.38; p = 0.0005). Again, this response was independent of baseline Hgb level. We also observed moderate inverse correlation between change in regional oxygen delivery and corresponding change in OEF (r = -0.48; p < 0.001), suggesting that these changes largely occur in parallel within the same vulnerable regions. The number of vulnerable regions was reduced from a median of nine (IQR, 2-13) at baseline to four (1-14) after transfusion (p = 0.005, Wilcoxon signed rank test). Similarly, the number of regions with elevated OEF was reduced from median of seven (IQR, 1-14) to 2.5 (IQR, 0-10) after transfusion (p = 0.09).
DISCUSSION
This study reports the only direct multiparametric quantitative regional measurements of cerebral oxygen delivery and Hemoglobin (g/dL) 9.6 ± 1.4 10.8 ± 1.4 < 0.001
Arterial oxygen content (g/dL) 12.9 ± 1.8 14.5 ± 1.7 < 0.001
Data presented as mean ± sd; significance based on paired t tests.
extraction in a large cohort of patients with SAH at risk for DCI. Across a wide range of hemoglobin values, oxygen delivery rose globally after transfusion of one unit of RBCs, driven specifically by a selective and greater improvement in vulnerable brain regions, regardless of hemoglobin level. The results of this study establish physiologic proof-of-principle that transfusion improves cerebral oxygen delivery and challenges the paradigm that a restrictive transfusion strategy is appropriate for this subgroup of critically ill patients. Anemia is common in SAH and has been linked to cerebral infarcts and worse outcome (7, 20, 34, 35) . Hemoglobin levels fall below 12-13 g/dL in almost all patients. Support for transfusion in SAH, however, has been modest. Studies have reported a rise in regional brain oxygen tension after transfusion (36, 37) , which may or may not equate to a rise in delivery, as we have previously shown in head injury (28) . One prospective trial of 44 SAH randomized patients to a goal hemoglobin concentration of greater than 10 or 11.5 g/dL (15); there was a trend toward better outcome in the higher hemoglobin group.
Whether enhanced delivery translates into improved tissue outcome has yet to be determined; nonetheless, these data provide some insight. In brain regions considered vulnerable due to low baseline oxygen delivery, concomitant elevated OEF also fell, indicating better matching of delivery to metabolic demand and additional reserves to better tolerate any further reductions in perfusion.
In addition, our study extends our understanding of the physiology of transfusion as a means of improving cerebral tolerance to ischemia, especially in those milder degrees of anemia. We did not find, as has been proposed on theoretical grounds (24) and widely integrated into practice, a hemoglobin threshold above which the benefit of transfusion is negated by a fall in CBF due to higher viscosity. Instead, we found that up to a Hgb of 13 g/dL, especially in vulnerable regions of the brain, CBF remains relatively stable, resulting in higher oxygen delivery after transfusion.
A number of factors must be considered when interpreting these data. Although we have demonstrated that transfusion provides an immediate improvement in oxygen delivery, we did not determine whether this increase is sustained. This study was intended as a proof-of-concept study to test the hypothesis that transfusion would improve DO 2 in order to determine if, and what further study is warranted. In order to assess the durability of the response, a study where hemoglobin was maintained at particular targets over time will be required.
Without a control group, we cannot state definitively say that the response was not due to a hemodynamic effect. We previously studied a cohort of SAH patients receiving a large saline bolus (15 mL/Kg) and found no effect on global CBF and a modest rise in vulnerable regions. More importantly, in the present study, DO 2 rose in response to the higher Cao 2 and CBF did not change indicating that the response was due to the hemoglobin not the volume.
While DO 2 rose and OEF fell in vulnerable regions, CMRo 2 did not rise; delivery was improved but utilization did not rise as would be expected in ischemic tissue. We believe there are a number of possible explanations for this finding: 1) Our definition of vulnerable regions identifies regions with oligemia that are at risk for ischemia (reduced but sufficient DO 2 ) which may or may not include areas with true ischemia (insufficient DO 2 to meet metabolic demands). Since oligemic tissue maintains adequate DO 2 at the expense of increased extraction, it has minimal reserves to be able to tolerate further insults. In that case when DO 2 rises, OEF will fall but CMRo 2 will not change, as occurred in this study.
2) The ischemic state is relatively short lived as the tissue soon dies; the likelihood of catching that dynamic using two snapshot measurements of CMRo 2 in each patient is quite low. 3) Due to the limited resolution of PET, our regions have to be fairly large (spherical regions of 10-mm diameter) and may have blended areas of oligemia and ischemia diluting the measured impact on CMRo 2 . In addition, the benefit of transfusion is relatively modest (i.e., a 10-15% rise in oxygen delivery); it remains to be determined if transfusion of more than one unit of blood would offer additional benefit. Furthermore, any physiologic benefits to oxygen delivery must be balanced against possible risks of transfusion, as suggested in observational studies of SAH patients (38, 39) .
While a majority of all those studied responded with an improvement in oxygen delivery, a minority of patients did not. We explored factors that might influence the response to transfusion and found unexpectedly that this was not driven by hemoglobin level, but rather baseline perfusion was the best predictor of the magnitude of the response; the presence of hypoperfusion was associated with a more robust response. If we could predict those with persistently low CBF and regions at risk despite routine medical therapy, perhaps transfusion could be an adjunctive intervention to improve oxygen delivery for these patients. This suggests a role for monitoring of CBF in SAH patients as an even better physiologic transfusion trigger than hemoglobin or even presence of neurologic symptoms.
While this study alone does not provide adequate clinical evidence to support a change in transfusion practice, it supports and informs future clinical trials and, at least, argues against a uniformly restrictive approach to transfusion in SAH patients. Given that there remains significant uncertainty about when and to what hemoglobin to transfuse in SAH (40), our findings provide physiologic support for a less restrictive transfusion strategy if DCI is a major concern and set the stage for definitive outcome trials of transfusion in SAH patients.
